Torsten Hoffmann

Biography

"Torsten joined Silence as Chief Operating Officer in June 2017. He has over 20 years of international R&D management experience. Prior to joining Silence, Torsten served as Chief Scientific Officer and Managing Director at Proteros from July 2015, and before then as Chief Scientific Officer and Executive Vice President at Zealand Pharma from July 2013. He previously spent 16 years at Roche in roles of increasing responsibility up to Site Head of Medicinal Chemistry at the company head quarter in Switzerland, and Head of the Global Roche Postdoc fellowship program. Torsten is the lead inventor of the anti-emetic medicine Netupitant, discovered at Roche and approved by the FDA as Akynzeo© in 2014. Torsten has a PhD in Chemistry from the ETH Zürich, Switzerland, which was followed by a role as research associate at the Scripps Research Institute in La Jolla, California. He has authored more than 85 publications, patent applications and published conference reports and has served on advisory boards. His awards include the Feodor Lynen award and a fellowship from the Alexander von Humboldt Foundation, Germany. "

Research Interest

RNAi therapeutics, peptides and small molecules, drug candidate progression to clinical development, R&D management